Welcome to our dedicated page for Medifast SEC filings (Ticker: MED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medifast’s weight-loss meal plans may look simple on the surface, but its SEC disclosures tell a deeper story about coach networks, inventory swings, and regulatory risk. If you have ever asked “Medifast SEC filings explained simply” or “Where can I track Medifast insider trading Form 4 transactions,” this page is built for you.
Stock Titan’s AI reads every Medifast filing the moment it lands on EDGAR. Need the Medifast quarterly earnings report 10-Q filing without combing through footnotes? Our AI-powered summaries surface margin changes, coach counts, and deferred revenue in seconds. Looking for Medifast executive stock transactions Form 4? Real-time alerts flag each sale or purchase so you never miss a signal.
Here’s how each form connects to Medifast’s business:
- 10-K annual report: Coach retention rates, segment revenue, and risk factors—see the Medifast annual report 10-K simplified by our AI.
- 10-Q: Quarter-over-quarter inventory and advertising spend—perfect for quick Medifast earnings report filing analysis.
- 8-K material events: Product recalls or leadership changes? Find Medifast 8-K material events explained in plain English.
- Form 4: Monitor Medifast Form 4 insider transactions real-time and spot buying before new program launches.
- DEF 14A proxy: Review Medifast proxy statement executive compensation to see how management pay aligns with coach growth.
Whether you’re comparing GLP-1 strategy disclosures or understanding Medifast SEC documents with AI, our platform converts dense filings into clear, actionable insights—updated the moment Medifast hits “submit.”
Medifast Schedule 13G filing summary The reporting entities—G1 Execution Services, LLC; Susquehanna Fundamental Investments, LLC; and Susquehanna Securities, LLC—report aggregate beneficial ownership of 785,606 shares, representing 7.2% of Medifast's outstanding common stock based on 10,938,000 shares outstanding as of June 30, 2025. The filing expressly states that the Susquehanna Securities total includes options to acquire 695,200 shares.
The filing includes a certification that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control. The report is executed and signed on August 13, 2025. No additional transactions, plans, or intentions are disclosed in this statement.
Medifast Director Xian Ming received two grants of Restricted Stock Units (RSUs) on June 25, 2025:
- 11,167.65 cash-settled RSUs as part of director compensation, vesting fully on June 25, 2026
- 6,013.35 additional RSUs valued at $13.39 per share (based on 20-day moving average), elected in lieu of cash compensation
Both RSU grants will be payable in cash upon Ming's termination of service as director. Following these transactions, Ming beneficially owns 26,129.568 RSUs from the first grant and 32,142.918 RSUs from the second grant. The RSUs were granted under Medifast's Director's Deferred Compensation Plan and the Amended and Restated 2012 Share Incentive Plan.
Medifast Director Scott Schlackman received 11,168 restricted stock units (RSUs) on June 25, 2025, as part of the company's Director's Deferred Compensation Plan. The RSUs were granted at $0 cost and represent the right to receive an equivalent number of common shares.
Key details of the transaction:
- The RSUs will fully vest on June 25, 2026
- Shares are granted under the Amended and Restated 2012 Share Incentive Plan
- Following the transaction, Schlackman owns 25,548.707 shares directly
- The grant is part of annual director compensation
The Form 4 was filed through an attorney-in-fact, Jason L. Groves, on June 26, 2025, within the required reporting timeline for insider transactions.
Director Andrea B Thomas of Medifast received 11,168 restricted stock units (RSUs) on June 25, 2025, as part of the Director's Deferred Compensation Plan. The RSUs were granted under the company's Amended and Restated 2012 Share Incentive Plan.
Key details of the transaction:
- RSUs were granted at $0 cost to the director
- Each unit represents one share of Medifast common stock
- Full vesting scheduled for June 25, 2026
- Following the transaction, Thomas owns 24,017.123 shares directly
This grant represents standard director compensation rather than an open market transaction. The filing was submitted by attorney-in-fact Jason L. Groves on June 26, 2025, within the required reporting timeframe.
Director Michael A. Hoer of Medifast received a significant equity grant of 11,168 restricted stock units (RSUs) on June 25, 2025, as part of the company's Director's Deferred Compensation Plan. The RSUs were granted at $0 cost and will fully vest on June 25, 2026.
Key details of the transaction:
- Each RSU represents the right to receive one share of Medifast common stock
- The grant was made under the Amended and Restated 2012 Share Incentive Plan
- Following the transaction, Hoer owns 26,139.473 shares directly
- The RSUs were granted in connection with annual director compensation
This Form 4 filing, signed by attorney-in-fact Jason L. Groves, indicates continued alignment of director interests with shareholders through equity-based compensation.
Medifast director Elizabeth A. Geary received 11,168 restricted stock units (RSUs) on June 25, 2025 as part of the company's Director's Deferred Compensation Plan. The RSUs were granted at $0 cost and will fully vest on June 25, 2026.
Key details:
- Each RSU represents the right to receive one share of Medifast common stock
- The grant was made under the Amended and Restated 2012 Share Incentive Plan
- Following the transaction, Geary directly owns 19,545 shares
- The RSUs were granted in connection with annual director compensation
This Form 4 filing indicates standard director equity compensation practices at Medifast, with a one-year vesting period for director RSU grants.
Medifast Director Jeffrey J. Brown reported significant stock acquisitions on June 25, 2025, through multiple transactions:
- Received 11,167.542 restricted stock units under the Director's Deferred Compensation Plan, which will fully vest on June 25, 2026
- Acquired 9,449.458 shares of common stock at $13.39 per share in lieu of cash compensation for director services
Following these transactions, Brown's total beneficial ownership includes:
- 38,577.647 shares held directly
- 4,232.967 shares held indirectly through the Jeffrey Brown Living Trust
The stock price was calculated using the 20-day moving average as of June 6, 2025. This Form 4 filing demonstrates significant insider accumulation of shares through compensation arrangements, suggesting continued alignment with shareholder interests.
FAQ
What is the current stock price of Medifast (MED)?
What is the market cap of Medifast (MED)?
